Xeris Biopharma (XERS) Competitors

Xeris Biopharma logo
$16.77 +0.07 (+0.42%)
As of 01:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

XERS vs. CORT, AXSM, AMRX, LNTH, and BLTE

Should you buy Xeris Biopharma stock or one of its competitors? Xeris Biopharma's main competitors and comparable companies include Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Amneal Pharmaceuticals (AMRX), Lantheus (LNTH), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Xeris Biopharma compare to Corcept Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Corcept Therapeutics has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$291.85M10.56$550K-$0.05N/A
Corcept Therapeutics$761.41M9.99$99.65M$1.2754.72

Corcept Therapeutics has a net margin of 16.53% compared to Xeris Biopharma's net margin of -1.76%. Xeris Biopharma's return on equity of 147.75% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-1.76% 147.75% 6.03%
Corcept Therapeutics 16.53%22.56%17.83%

In the previous week, Xeris Biopharma had 3 more articles in the media than Corcept Therapeutics. MarketBeat recorded 8 mentions for Xeris Biopharma and 5 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.88 beat Xeris Biopharma's score of 0.59 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xeris Biopharma presently has a consensus target price of $17.00, indicating a potential upside of 0.81%. Corcept Therapeutics has a consensus target price of $139.50, indicating a potential upside of 100.75%. Given Corcept Therapeutics' higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Xeris Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Corcept Therapeutics beats Xeris Biopharma on 11 of the 15 factors compared between the two stocks.

How does Xeris Biopharma compare to Axsome Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Xeris Biopharma currently has a consensus target price of $17.00, suggesting a potential upside of 0.81%. Axsome Therapeutics has a consensus target price of $266.21, suggesting a potential upside of 94.32%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.86

Xeris Biopharma has higher earnings, but lower revenue than Axsome Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$291.85M10.56$550K-$0.05N/A
Axsome Therapeutics$638.50M11.29-$183.17M-$3.06N/A

Xeris Biopharma has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 10 more articles in the media than Xeris Biopharma. MarketBeat recorded 18 mentions for Axsome Therapeutics and 8 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.59 beat Axsome Therapeutics' score of 0.22 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Axsome Therapeutics
1 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Xeris Biopharma has a net margin of -1.76% compared to Axsome Therapeutics' net margin of -18.18%. Xeris Biopharma's return on equity of 147.75% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-1.76% 147.75% 6.03%
Axsome Therapeutics -18.18%-198.73%-22.03%

Summary

Axsome Therapeutics beats Xeris Biopharma on 11 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Xeris Biopharma (NASDAQ:XERS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Xeris Biopharma presently has a consensus price target of $17.00, suggesting a potential upside of 0.81%. Amneal Pharmaceuticals has a consensus price target of $23.00, suggesting a potential upside of 8.41%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Amneal Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Xeris Biopharma had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Xeris Biopharma and 6 mentions for Amneal Pharmaceuticals. Xeris Biopharma's average media sentiment score of 0.59 beat Amneal Pharmaceuticals' score of 0.53 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amneal Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Xeris Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$291.85M10.56$550K-$0.05N/A
Amneal Pharmaceuticals$3.20B2.12$72.06M$0.4250.51

Amneal Pharmaceuticals has a net margin of 4.17% compared to Xeris Biopharma's net margin of -1.76%. Amneal Pharmaceuticals' return on equity of 283.50% beat Xeris Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-1.76% 147.75% 6.03%
Amneal Pharmaceuticals 4.17%283.50%7.79%

Summary

Amneal Pharmaceuticals beats Xeris Biopharma on 12 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Lantheus?

Xeris Biopharma (NASDAQ:XERS) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Xeris Biopharma had 2 more articles in the media than Lantheus. MarketBeat recorded 8 mentions for Xeris Biopharma and 6 mentions for Lantheus. Lantheus' average media sentiment score of 0.67 beat Xeris Biopharma's score of 0.59 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lantheus
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lantheus has a net margin of 17.28% compared to Xeris Biopharma's net margin of -1.76%. Xeris Biopharma's return on equity of 147.75% beat Lantheus' return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-1.76% 147.75% 6.03%
Lantheus 17.28%29.26%15.40%

Xeris Biopharma presently has a consensus price target of $17.00, suggesting a potential upside of 0.81%. Lantheus has a consensus price target of $107.44, suggesting a potential upside of 5.55%. Given Lantheus' higher probable upside, analysts clearly believe Lantheus is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Lantheus
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21

Xeris Biopharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Lantheus has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$291.85M10.56$550K-$0.05N/A
Lantheus$1.56B4.26$233.56M$4.0625.07

Summary

Lantheus beats Xeris Biopharma on 9 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Belite Bio?

Xeris Biopharma (NASDAQ:XERS) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xeris Biopharma presently has a consensus target price of $17.00, suggesting a potential upside of 0.81%. Belite Bio has a consensus target price of $226.91, suggesting a potential upside of 38.60%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Belite Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

Xeris Biopharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.19, meaning that its share price is 219% less volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Belite Bio. Xeris Biopharma is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$291.85M10.56$550K-$0.05N/A
Belite BioN/AN/A-$77.61M-$2.73N/A

In the previous week, Belite Bio had 17 more articles in the media than Xeris Biopharma. MarketBeat recorded 25 mentions for Belite Bio and 8 mentions for Xeris Biopharma. Belite Bio's average media sentiment score of 0.60 beat Xeris Biopharma's score of 0.59 indicating that Belite Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Belite Bio
4 Very Positive mention(s)
6 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Belite Bio has a net margin of 0.00% compared to Xeris Biopharma's net margin of -1.76%. Xeris Biopharma's return on equity of 147.75% beat Belite Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-1.76% 147.75% 6.03%
Belite Bio N/A -9.92%-9.75%

Summary

Belite Bio beats Xeris Biopharma on 8 of the 15 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XERS vs. The Competition

MetricXeris BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.07B$13.63B$7.76B$11.63B
Dividend YieldN/A2.58%2.46%4.43%
P/E Ratio-335.7729.4734.2929.91
Price / Sales10.507.018.485.64
Price / Cash166.2215.7421.9322.50
Price / Book62.115.114.393.67
Net Income$550K$2.88B$3.51B$392.03M
7 Day Performance5.94%-3.90%-5.19%-3.98%
1 Month Performance62.66%-4.91%-4.33%-6.46%
1 Year Performance130.99%-7.41%-1.33%-6.95%

Xeris Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XERS
Xeris Biopharma
2.0119 of 5 stars
$16.77
+0.4%
$17.00
+1.4%
+132.6%$3.07B$291.85MN/A435
CORT
Corcept Therapeutics
3.8952 of 5 stars
$75.33
+0.4%
$139.50
+85.2%
-8.4%$8.31B$761.41M59.77730
AXSM
Axsome Therapeutics
3.5141 of 5 stars
$140.24
+4.7%
$267.58
+90.8%
-1.9%$7.36B$638.50MN/A925
AMRX
Amneal Pharmaceuticals
3.5903 of 5 stars
$21.21
-0.3%
$23.00
+8.4%
+82.4%$6.76B$3.02B50.388,500
LNTH
Lantheus
2.4337 of 5 stars
$101.40
+0.4%
$107.44
+6.0%
+91.9%$6.62B$1.54B24.981,193

Related Companies and Tools


This page (NASDAQ:XERS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners